Navigation Links
Advancement in tissue engineering promotes oral wound healing
Date:2/2/2009

Tampa, Fla. (Feb. 3rd, 2009) Oral tissue engineering for transplantation to aid wound healing in mouth (oral cavity) reconstruction has taken a significant step forward with a Netherlands-based research team's successful development of a gum tissue (gingival) substitute that can be used for reconstruction in the oral cavity. Their work was reported in the current issue of Cell Transplantation (17:10/11).

According to the study's lead author, Dr. Susan Gibbs of the VU University Medical Centre in Amsterdam, skin substitutes have been far more advanced than oral gingiva substitutes and, until now, no oral tissue-engineered products have been available for clinical applications. The team was the first to develop an autologous (same patient) full thickness skin substitute that Dr. Gibbs says is "proving to be very successful." However, they wanted to develop an autologous, full thickness oral substitute with the correct oral characteristics.

"Reconstructive surgery within the oral cavity is required during tumor excision, cleft palate repair, trauma, repair of diseased tissue and for generating soft tissue around teeth and dental implants," explained Dr. Gibbs. "Drawbacks of using skin as an autograft material in the oral cavity include bulkiness, sweating and hair formation and the limited amount of donor tissue available."

Their current study was aimed at constructing analogous, full-thickness oral substitutes in a similar manner to their skin substitute while maintaining the needed characteristics for successful oral transplantation. They used small amounts of patient oral tissue obtained from biopsies, then cultured and expanded the tissues in vitro over a three-week period.

Results of their study with a small number of patients showed that the gingiva substitute was "promising" and supported the need to carry out a larger patient study in the future.

"This study emphasized the importance of closely matching
'/>"/>

Contact: Dr. Susan Gibbs
s.gibbs@vumvc.nl
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

1

GOOD

Page: 1 2

Related biology news :

1. Frontiers in Optics presents scientific advancements
2. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
3. Leading researchers and experts gather to discuss latest advancements in drug discovery
4. American Association for the Advancement of Science honors four Iowa Staters
5. 13 UCR faculty members recognized by American Association for the Advancement of Science
6. A step toward tissue-engineered heart structures for children
7. Researchers create system to build transplant tissue
8. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Knocking out cell receptor may help block fat deposits in tissues, prevent weight gain
11. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
Breaking Biology News(10 mins):How nutrition affects healthy aging 2New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 1Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 2Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 3Traumatic brain injury caused by exposure to explosive blast presents critical challenge 49434 1Traumatic brain injury caused by exposure to explosive blast presents critical challenge 49434 2Antibiotics take toll on beneficial microbes in gut 8909 1Antibiotics take toll on beneficial microbes in gut 8909 2Antibiotics take toll on beneficial microbes in gut 8909 3
... PLAIN, N.Y., JULY 27, 2008 In a new March of Dim...tentially deadly disorder that affects about 5 per...s in mice that may have important implications for....D., Ph.D., and Rodney E. Kellems, Ph.D., Departme...n M. Ramin, M.D., Department of Obstetrics, Gyneco...
...MINGHAM, Ala. The life expectancy for patients wi...d by more than 13 years since the late 1990s thank...ding to researchers at the University of Alabama a...Vancouver, British Columbia. , Improved survival ... among 43,355 HIV-positive study participants in E...
...GO (July 25, 2008) New research published in the ... of Surgeons shows elevated plasma DNA is a relia...dy also suggests that plasma DNA levels rise befor...jority of patients. , Esophageal cancer, one of...usually diagnosed at a late stage. An accurate mar...
Other Biology News:New research on pre-eclampsia in mice may have important implications for humans 2Anti-HIV therapy boosts life expectancy more than 13 years 2Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds 2
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
...ewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:...io of therapeutic,proteins for metabolic and cardi...gible to proceed with its planned Phase I/II human... the 30-day review period of its,Investigational N...bmitted,the application in July to the U.S. Food a...
...ins momentum with launch of a Phase ...LE, Md., Sept. 16 Novavax, Inc.,(Nasdaq: NVAX ) ...in a Phase,II clinical trial of its virus-like par...Phase IIa randomized, placebo controlled clinical ...of different doses of its seasonal,influenza VLP v...
...l/ - MIGENIX Inc. (the,"Company" or "MIGENIX") (TS... drugs for infectious diseases, reports financial ...nd provides a corporate update on its programs,and...AMS, Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226;...related infections): Cadence Pharmaceuticals, Inc....
Other Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11
Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc
Rabbit Anti-Raf1 Polyclonal Antibody, Unconjugated from Abcam
Sheep Anti-Human hCG beta core fragment Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-SIT Monoclonal Antibody, Unconjugated, Clone SIT-01 from Abcam
Biology Products: